Copyright@ Institutional Investor, Inc. All rights reserved. influences, and active risk, which
cannot be explained by marketwide factors. In this framework, active risk represents the …

The standard deviation of investment returns is widely accepted as the best, and perhaps
only commonly used indicator of portfolio risk in the investment management business. …

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

The authors start with the observation that traditional asset allocation processes fail to integrate
the two important sources of portfolio risk: systematic and active. They introduce a new …

The author investigates the relationship between a manager's ability to add value and the
way the relevant benchmark index is constructed. He first observes that the larger the number …

PURPOSE For patients with hormone receptor–positive (HR+), human epidermal growth
factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), first-line treatment is …

If a manager has an outstanding track record, how can we tell how much this past success
is due to luck versus skill? The complex nature of active portfolio management makes this …

In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is
commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (…

Arguably, two of the most important decisions a consultant or plan sponsor can make involve
1) the allocation of funds across asset classes and 2) the implementation of the targeted …

Purpose of Review CDK4/6 inhibition (CDK4/6i) is a key component of first-line combination
treatment with endocrine therapy for hormone receptor-positive, HER2-negative metastatic …